Literature DB >> 22622470

Lymph node dissection after chemoradiation in esophageal cancer: a subgroup analysis of patients with and without pathological response.

Yin-Kai Chao1, Hui-Ping Liu, Ming-Ju Hsieh, Yi-Cheng Wu, Yun-Hen Liu, Chi-Hsiao Yeh, Hsien-Kun Chang, Chen-Kan Tseng.   

Abstract

BACKGROUND: Extensive lymph node dissection (LND) is beneficial in primarily resected esophageal cancer patients. Such benefit was believed to be seen in neoadjuvant chemoradiotherapy (CRT)-treated patients, but evidence was inconsistent. We hypothesized that CRT might offset the benefit of LND in certain subgroup of patients, especially in major responders.
METHODS: The clinical pathological data and survival of esophageal squamous cell carcinoma patients who received curative resection after CRT between 1996 and 2007 were analyzed. On the basis of the mean LND number of the cohort, patients were divided into two groups: group 1, lower LND, and group 2, higher LND.
RESULTS: The cohort comprised 303 patients (295 men and 8 women) with a mean age of 55.4 years. There were 179 patients in group 1 and 124 patients in group 2. One hundred one patients had pathological complete response (pCR). There were more pCR in group 1 (38 vs. 26.6%, P = 0.039) and more lymph node positive cases in group 2 (16 vs. 27.4%, P = 0.018). Extent of LND had no survival difference in the entire cohort (overall survival 32 vs. 38%, P = 0.31). With the stratification analysis according to tumor response, inadequate LND exhibited negative impact in patients who did not experience pCR (P = 0.027). Without adequate LND, the survival of ypTxN0 was equally poor as ypN-positive cases (overall survival 15 vs. 16%, P = 0.791). In the pCR group, the extent of LND had an impact on survival.
CONCLUSIONS: The effect of LND was influenced by tumor response after CRT. There is a strong survival benefit for extensive LND after CRT in esophageal squamous cell carcinoma, especially in non-pCR patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622470     DOI: 10.1245/s10434-012-2402-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Total number of lymph nodes in oncologic resections, is there more to be found?

Authors:  Kirsten J de Burlet; Mari F C M van den Hout; Hein Putter; Vincent T H B M Smit; Henk H Hartgrink
Journal:  J Gastrointest Surg       Date:  2015-02-18       Impact factor: 3.452

2.  PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.

Authors:  Nelson Adami Andreollo; Giovanni de Carvalho Beraldo; Iuri Pedreira Filardi Alves; Valdir Tercioti-Junior; José Antonio Possato Ferrer; João de Souza Coelho-Neto; Luiz Roberto Lopes
Journal:  Arq Bras Cir Dig       Date:  2018-12-06

3.  Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study.

Authors:  Yan Zheng; Yin Li; Xianben Liu; Ruixiang Zhang; Zongfei Wang; Haibo Sun; Shilei Liu
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

4.  Impact of the number of resected lymph nodes on survival after preoperative radiotherapy for esophageal cancer.

Authors:  San-Gang Wu; Zhao-Qiang Zhang; Wen-Ming Liu; Zhen-Yu He; Feng-Yan Li; Huan-Xin Lin; Jia-Yuan Sun; Hui Lin; Qun Li
Journal:  Oncotarget       Date:  2016-04-19

5.  Lymph Node Status after Neoadjuvant Chemoradiation Therapy for Esophageal Cancer according to Radiation Field Coverage.

Authors:  Sang Yoon Kim; Samina Park; In Kyu Park; Young Tae Kim; Chang Hyun Kang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2019-10-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.